Connect with us

Technology

Lucid Group, Inc. Announces Proposed Convertible Senior Notes Offering

Published

2 years ago

on

NEWARK, Calif., April 2, 2025 /PRNewswire/ — Lucid Group, Inc. (Nasdaq: LCID) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2030 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Lucid also expects to grant the initial purchasers of the notes an option, for settlement within a period of 13 days from, and including, the date the notes are first issued, to purchase up to an additional $100,000,000 principal amount of notes.

The Notes

The notes will be senior, unsecured obligations of Lucid, will accrue interest payable semi-annually in arrears, and will mature on April 1, 2030, unless earlier repurchased, redeemed, or converted. Noteholders will only have the right to convert their notes in certain circumstances and during specified periods. Lucid will settle conversions of notes by paying or delivering, as applicable, cash, shares of its Class A common stock, or a combination of cash and shares of its common stock, at Lucid’s election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Lucid’s option at any time, and from time to time, on or after April 6, 2028 and on or before the 31st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Lucid’s common stock exceeds 130% of the conversion price for a specified period of time and certain liquidity conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

Lucid intends to use the net proceeds of the offering, after deducting the initial purchasers’ discounts and commissions and its estimated offering expenses, to (i) repurchase a portion of its outstanding 1.25% Convertible Senior Notes due 2026 and (ii) pay the cost of the capped call transactions described below. To the extent there are any remaining net proceeds from this offering, Lucid intends to use such remainder for general corporate purposes.

Capped Call Transactions

In connection with the offering, Lucid expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers of the notes or their respective affiliates and/or other financial institutions. The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Lucid’s common stock that will initially underlie the notes. The capped call transactions are expected generally to reduce potential dilution to Lucid’s common stock upon conversion of the notes and/or offset any cash payments that Lucid could be required to make in excess of the principal amount of any converted notes upon conversion thereof, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Lucid expects to enter into additional capped call transactions with the capped call counterparties.

Repurchases of Outstanding 2026 Notes

Concurrently with the offering, Lucid expects to enter into one or more separate and individually negotiated transactions with one or more holders of the 2026 notes to repurchase for cash a portion of the 2026 notes on terms to be negotiated with each holder.

Ayar Prepaid Forward Transaction

In connection with the pricing of the notes, Lucid expects Ayar Third Investment Company (“Ayar”), a wholly-owned subsidiary of the Public Investment Fund of Saudi Arabia to enter into a privately negotiated prepaid forward transaction with a forward counterparty that is an affiliate of one of the initial purchasers, pursuant to which Ayar will purchase a number of shares of Lucid’s common stock with delivery expected to occur on or about the maturity date for the notes, subject to the ability of the forward counterparty to elect to settle all or a portion of the prepaid forward transaction early. Subject to the conditions set forth in the agreement governing the prepaid forward transaction, the prepaid forward transaction will be settled physically, subject to Ayar’s option to elect cash settlement of the prepaid forward transaction. Lucid will not be a party to the prepaid forward transaction.

The prepaid forward transaction is generally intended to facilitate privately negotiated derivative transactions, including swaps, between the forward counterparty or its affiliates and investors in the notes relating to Lucid’s common stock by which investors in the notes will hedge their investments in the notes. Ayar’s entry into the prepaid forward transaction with the forward counterparty and the entry by the forward counterparty into derivative transactions in respect of Lucid’s common stock with the investors of the notes could have the effect of increasing (or reducing the size of any decrease in) the market price of Lucid’s common stock concurrently with, or shortly after, the pricing of the notes and effectively raising the initial conversion price of the notes.

The offer and sale of the notes and any shares of Lucid’s common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Lucid’s common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

Additional information about the transactions described in this press release can be found in the Current Report on Form 8-K that Lucid intends to file with the Securities and Exchange Commission on the same date of this press release.

About Lucid Group

Lucid (NASDAQ: LCID) is a Silicon Valley-based technology company focused on creating the most advanced EVs in the world. The award-winning Lucid Air and new Lucid Gravity deliver best-in-class performance, sophisticated design, expansive interior space and unrivaled energy efficiency. Lucid assembles both vehicles in its state-of-the-art, vertically integrated factory in Arizona. Through its industry-leading technology and innovations, Lucid is advancing the state-of-the-art of EV technology for the benefit of all.

Investor Relations Contact

investor@lucidmotors.com

Media Contact

media@lucidmotors.com

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “shall,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering and capped call transactions, the anticipated effects of entering into the capped call transactions, the intended use of the net proceeds from the offering, including the 2026 notes repurchases, and the anticipated terms of the prepaid forward transaction. Actual events and circumstances may differ from these forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Among those risks and uncertainties are market conditions, including market interest rates, the trading price and volatility of Lucid’s common stock and risks relating to Lucid’s business, including those factors discussed under the heading “Risk Factors” in Part I, Item 1A of Lucid’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as in other documents Lucid has filed or will file with the Securities and Exchange Commission. If any of these risks materialize or Lucid’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Lucid currently does not know or that Lucid currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Lucid may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above. In addition, forward-looking statements reflect Lucid’s expectations, plans or forecasts of future events and views as of the date of this communication. Lucid anticipates that subsequent events and developments will cause Lucid’s assessments to change. However, while Lucid may elect to update these forward-looking statements at some point in the future, Lucid specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-group-inc-announces-proposed-convertible-senior-notes-offering-302418994.html

SOURCE Lucid Group

Related Topics:
Continue Reading

Technology

Amid Rising Costs and Surgical Disruptions in ASCs, NorthStar Anesthesia Strengthens Focus on ASC Partnerships

Published

47 minutes ago

on

October 23, 2026

By

With 17 new ASC partnerships nationwide to date in 2026, NorthStar Anesthesia emphasizes proactive patient assessment, reliable staffing, and clinical consistency to help surgery centers reduce preventable cancellations and maximize surgical capacity.

IRVING, Texas, Oct. 23, 2026 /PRNewswire/ — As ambulatory surgery centers (ASCs) face mounting financial pressures, staffing challenges, and increasingly complex patient needs, anesthesia has emerged as a critical partner in their ability to operate efficiently and sustainably. NorthStar Anesthesia is addressing these challenges through a dedicated ASC model designed to reduce preventable case cancellations, improve surgical throughput, and help centers make the most of their existing operating room capacity.

NorthStar celebrates 17 new ASC partnerships nationwide to date in 2026.

“The challenge for ASCs today isn’t simply finding anesthesia coverage. It’s ensuring that coverage translates into reliable surgical capacity,” said Cindy Myers, Vice President of ASC Operations at NorthStar Anesthesia. “When cases are cancelled unnecessarily or operating rooms aren’t running as planned, the impact extends well beyond the anesthesia department. Our focus is on helping centers address those challenges systematically, so they can deliver more consistent care and operate more efficiently.”

Reducing Preventable Cancellations Through Better Preparation

One of the most significant opportunities to improve ASC performance lies in the preoperative process. When potential anesthesia concerns are not identified until the day of surgery, patients may face unexpected cancellations, surgeons lose valuable operating time, and centers absorb the cost of unused capacity.

NorthStar addresses this challenge through ASC-specific pre-anesthesia testing (PAT) guidelines and standardized clinical protocols designed to identify potential issues earlier, facilitate appropriate patient optimization, and support consistent decision-making across the surgical process.

“In ambulatory surgery, the decisions made before the patient arrives are often just as important as those made in the operating room,” said Gajan Mahendran, MD, Vice President of Physician Services at NorthStar Anesthesia. “A consistent, evidence-based approach to preoperative assessment helps us identify risks earlier, determine which patients are appropriate for the ASC setting, and address potential barriers to surgery in advance. That means fewer last-minute surprises and a better experience for patients, surgeons, and facilities.”

Aligning Anesthesia Resources With Surgical Demand

Alongside clinical challenges, ASCs are navigating a changing economic environment. In a recent Becker’s ASC Review interview, NorthStar CEO Adam Spiegel noted that approximately 80% of ASCs in NorthStar’s network now require anesthesia stipends, compared with just 10% to 15% before the pandemic.

As anesthesia costs rise, ensuring that staffing levels align with actual surgical demand has become increasingly important. NorthStar works with ASC partners to develop staffing models that reflect each facility’s case mix, surgical volume, and operating requirements. “Adding anesthesia resources doesn’t automatically improve performance if those resources aren’t aligned with the center’s surgical volume,” Myers said. “We work closely with our partners to understand their schedules, case mix, and operational needs so we can build a model that supports both reliable access to care and financial sustainability.”

Combining National Resources With Local Clinical Expertise

As ASCs take on a greater share of surgical procedures, the demands placed on anesthesia providers are becoming more complex. Smaller or locally managed anesthesia groups may face challenges maintaining consistent coverage, recruiting clinicians, or investing in standardized clinical and operational processes.

NorthStar’s model combines local clinical leadership with national recruiting capabilities, dedicated ASC operations expertise, and established quality guidelines. This infrastructure helps support continuity of care, consistent clinical practices, and the flexibility to respond to changes in surgical demand.

The approach is reflected in NorthStar’s expanding ASC partnerships.  To date in 2026 alone, NorthStar has added 17 ASC partnerships, including CarePlex Orthopaedic Ambulatory Surgery Center in Norfolk, Virginia; Stony Point Surgery Center and West Creek Surgery Center, both part of MedRVA Healthcare in Richmond, Virginia; an Orthopedic Surgery Center in Wisconsin; Eye Surgery Center of Homewood in Homewood, Alabama; and The Toledo Clinic ASC in Toledo, Ohio.

These partnerships reflect the growing importance of anesthesia providers that can address both the clinical and operational needs of outpatient surgery centers.

To learn more and to request a confidential anesthesia program assessment, please contact James Bagliani, Director of Business Development, NorthStar Anesthesia at james.bagliani@northstaranesthesia.com. 

About NorthStar Anesthesia

NorthStar Anesthesia is a company of caregivers, founded by an anesthesiologist and a Certified Registered Nurse Anesthetist (CRNA). With more than 4,000 anesthesiologists and CRNAs under its banner, NorthStar partners with more than 280 healthcare client sites across more than 20 states and counting to deliver a more productive and efficient model of anesthesia care. Its care team approach focuses on the provision of high-quality care while measurably improving operating room performance.

Media Contact: James Bagliani, Director of Business Development, NorthStar Anesthesia james.bagliani@northstaranesthesia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/amid-rising-costs-and-surgical-disruptions-in-ascs-northstar-anesthesia-strengthens-focus-on-asc-partnerships-302918226.html

SOURCE NorthStar Anesthesia

Continue Reading

Technology

Dimethylaminopropylamine Market to Reach USD 731.9 Million by 2035 on Surfactant and Epoxy Demand, Credence Research Finds

Published

47 minutes ago

on

October 23, 2026

By

LONDON, Oct. 23, 2026 /PRNewswire/ — Credence Research Inc. has added the “Dimethylaminopropylamine Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035” study to its market intelligence portfolio. The report examines market value, segmentation, demand drivers, regional dynamics, competition and recent industry developments.

The dimethylaminopropylamine (DMAPA) market was valued at USD 452.6 million in 2025 and is projected to reach USD 731.9 million by 2035, representing a 4.92% compound annual growth rate over 2025–2035, according to Credence Research. The firm estimates 2026 revenue at USD 474.3 million. Asia Pacific accounted for the largest modeled geographic share at 44.0% in 2025, while Asia Pacific is projected to grow fastest at 5.88% annually. Market sizes, regional shares and segment shares are Credence Research estimates rather than independently audited industry totals.

Key Takeaways

The market is forecast to increase from USD 452.6 million in 2025 to USD 731.9 million by 2035, with a reported CAGR of 4.92%.Asia Pacific led the modeled 2025 geography with 44.0%; Asia Pacific has the fastest forecast geographic growth of 5.88%.By application, Surfactants accounted for 61.0% of modeled 2025 value, while Epoxy curing agents is forecast to grow at 5.66% a year.By end-use industry, Personal care and cosmetics accounted for 44.0% of modeled 2025 value, while Paints, coatings and composites is forecast to grow at 5.61% a year.The market definition excludes adjacent product or transaction value where that spending is outside the report’s measured scope.

Scope & Segmentation – Dimethylaminopropylamine Market

The study values sales of 3-(dimethylamino)-1-propylamine, an amine intermediate produced from dimethylamine and acrylonitrile. Included uses span betaine and amine-oxide surfactants, epoxy curing agents, polyurethane catalysts, water treatment chemicals, agrochemical intermediates and lubricant additives. Finished surfactants, coatings and other downstream products are excluded from the DMAPA revenue estimate.

By application: Surfactants (betaines and amine oxides); Epoxy curing agents; Polyurethane catalysts; Water treatment chemicals; Agrochemical intermediates; Fuel and lubricant additives; Others.By end-use industry: Personal care and cosmetics; Home care and institutional cleaning; Paints, coatings and composites; Water treatment; Agriculture; Automotive and lubricants.By geography: Asia Pacific; Europe; North America; Latin America; Middle East and Africa.

Read the complete report and request a sample: https://www.credenceresearch.com/report/dimethylaminopropylamine-market 

Why This Report Matters

The study distinguishes a narrowly defined revenue pool from adjacent activity that can inflate comparisons between research estimates. This helps strategy teams compare suppliers, customer budgets and product categories on a consistent basis.The base-year segment mix identifies where current purchasing is concentrated, while the modeled faster-growing categories help evaluate investment timing and market entry.Geographic shares are proprietary estimates; company and regulatory announcements are used to explain demand mechanisms, not to independently verify global market totals.

Market Overview
The study values sales of 3-(dimethylamino)-1-propylamine, an amine intermediate produced from dimethylamine and acrylonitrile. Included uses span betaine and amine-oxide surfactants, epoxy curing agents, polyurethane catalysts, water treatment chemicals, agrochemical intermediates and lubricant additives. Finished surfactants, coatings and other downstream products are excluded from the DMAPA revenue estimate.

DMAPA is a building block for cocamidopropyl betaine and related surfactants used in shampoos, body washes and dishwashing products. Producers serving consumer brands require consistent quality and supply, so the largest application tends to support repeat orders rather than episodic equipment-style purchases.

The outlook reflects expected changes in customer adoption, procurement, technology and regulation. It should be read as a modeled scenario, not as a guarantee of sales or company performance.

Key Attributes

Attribute

Details

Base year

2025

Historical reference

2018–2025

2025 market size

USD 452.6 million

2026 estimate

USD 474.3 million

2035 market forecast

USD 731.9 million

Reported CAGR

4.92% (2025–2035)

Geographic scope

Global

Primary source

https://www.credenceresearch.com/report/dimethylaminopropylamine-market

Segmentation

By application
The study divides this category into surfactants (betaines and amine oxides); epoxy curing agents; polyurethane catalysts; water treatment chemicals; agrochemical intermediates; fuel and lubricant additives; others. Surfactants led the 2025 value mix with 61.0%. Epoxy curing agents is the fastest-growing modeled subsegment at 5.66% a year. These shares represent Credence Research model outputs, not audited supplier sales.

By end-use industry
The study divides this category into personal care and cosmetics; home care and institutional cleaning; paints, coatings and composites; water treatment; agriculture; automotive and lubricants. Personal care and cosmetics led the 2025 value mix with 44.0%. Paints, coatings and composites is the fastest-growing modeled subsegment at 5.61% a year. These shares represent Credence Research model outputs, not audited supplier sales.

Market Growth Drivers

Mild cleansing formulas sustain high-volume demand
DMAPA is a building block for cocamidopropyl betaine and related surfactants used in shampoos, body washes and dishwashing products. Producers serving consumer brands require consistent quality and supply, so the largest application tends to support repeat orders rather than episodic equipment-style purchases.

Epoxy hardeners provide a faster-growth outlet
DMAPA-based amidoamines are used in epoxy curing systems for floors, protective coatings and composite applications. Wind blade production and industrial maintenance provide additional demand. The report models epoxy curing agents as the fastest-growing application, although their value starts below surfactants.

Capacity integration shapes producer economics
The chemical route depends on dimethylamine and acrylonitrile, making feedstock access and energy costs important. Integrated producers can manage these inputs and purity requirements more directly, while regional buyers value dependable supply and local technical support.

Regional Analysis
Asia Pacific held 44.0% of modeled 2025 revenue, while Asia Pacific is expected to record the fastest regional growth at 5.88%. The allocation follows the study’s defined buyer or provider-revenue scope.

Asia Pacific
Asia Pacific represented 44.0% of modeled 2025 market value. China hosts extensive betaine and epoxy manufacturing and new intermediate capacity. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Europe
Europe represented 23.0% of modeled 2025 market value. Specialty formulations and high-purity specifications sustain demand. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

North America
North America represented 21.0% of modeled 2025 market value. Personal care, coating and water treatment buyers support a mature market. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Latin America
Latin America represented 7.0% of modeled 2025 market value. Brazilian and Mexican cleaning and personal care production expands. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Middle East and Africa
Middle East and Africa represented 5.0% of modeled 2025 market value. Industrial chemicals and water treatment provide emerging outlets. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Market Challenges

Input prices and possible overcapacity
Changes in acrylonitrile and dimethylamine costs can pressure margins. New Asian capacity could also exceed near-term demand, creating price competition, especially for producers that lack integrated feedstock or differentiated purity grades.

Handling and product-purity requirements
DMAPA is a hazardous industrial intermediate requiring careful handling. Residual amines in downstream betaines can create sensitization concerns, so cosmetics customers increasingly emphasize analytical control, specifications and supplier qualification.

Future Outlook
Asia Pacific should remain the main production and demand center, with surfactants anchoring volume and epoxy applications contributing above-average growth. Supplier positioning will depend on feedstock integration, reliable logistics, high-purity grades and the pace at which new capacity is absorbed.

Competitive Landscape
BASF and Eastman Chemical are identified as integrated DMAPA producers, while Zhangjiagang Feixiang Chemical and Zhejiang Xinhua Chemical participate in Chinese production. Huntsman is relevant to downstream amine chemistry. Solvay, Evonik and Kao are better described as converters or customers for DMAPA-based surfactants rather than direct merchant DMAPA producers. No credible company-specific DMAPA revenue ranking is available.

Key Players
BASF; Eastman Chemical; Zhangjiagang Feixiang Chemical; Zhejiang Xinhua Chemical; Huntsman (downstream derivatives); Solvay (surfactants); Evonik (surfactants); Kao (surfactants)

Recent Developments

Oct. 16, 2025: BASF said the July start-up of expanded DMAPA production in Nanjing nearly doubled the site’s annual capacity and raised BASF’s global DMAPA capacity by more than 20% to approximately 85,000 metric tons.July 2025: As part of the same Nanjing project, BASF expanded polyetheramine capacity by about 25%. This is a related amine-chain investment, not an additional DMAPA plant.

Report Coverage
The study provides market estimates for 2025 and 2035, a 2026 interim estimate, analysis of the defined product and service scope, segment and geographic revenue shares, demand drivers, technology changes, competitive roles, constraints and recent dated developments. The reported CAGR and regional shares are based on Credence Research’s market model. Company announcements are contextual evidence and should not be interpreted as independent verification of the forecast.

Read the complete report and request a sample: https://www.credenceresearch.com/report/dimethylaminopropylamine-market 

Related Reports

https://www.credenceresearch.com/report/apac-infectious-enteritis-treatment-market 

https://www.credenceresearch.com/report/australia-digital-therapeutics-market 

https://www.credenceresearch.com/report/australia-corporate-education-and-upskilling-market 

https://www.credenceresearch.com/report/prescription-drugs-market 

https://www.credenceresearch.com/report/orthopedic-devices-market 

https://www.credenceresearch.com/report/parkinsons-disease-therapeutics-market 

https://www.credenceresearch.com/report/plasma-derived-therapy-market 

https://www.credenceresearch.com/report/over-the-counter-drugs-market 

https://www.credenceresearch.com/report/orphan-drugs-market 

https://www.credenceresearch.com/report/pediatric-drugs-market 

https://www.credenceresearch.com/report/pain-management-drugs-market 

https://www.credenceresearch.com/report/osteoporosis-drugs-market 

https://www.credenceresearch.com/report/patient-monitoring-devices-market 

https://www.credenceresearch.com/report/australia-drive-by-wire-market 

https://www.credenceresearch.com/report/australia-cold-chain-and-refrigerated-transport-market 

https://www.credenceresearch.com/report/australia-critical-illness-insurance-market 

https://www.credenceresearch.com/report/asia-pacific-lysosomal-acid-lipase-deficiency-lal-d-treatment-market 

https://www.credenceresearch.com/report/australia-eco-friendly-labels-market 

https://www.credenceresearch.com/report/apac-healthcare-digital-twins-market 

https://www.credenceresearch.com/report/australia-electric-vehicle-charger-operations-and-maintenance-services-market 

https://www.credenceresearch.com/report/australia-driveline-components-market 

About Us
Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. It provides quantitative market research, competitive intelligence and strategic advisory services to businesses, investors and other organizations. Its research draws on primary and secondary information, industry interviews and structured market models.

The firm analyzes market size, growth drivers, segmentation, regional opportunities, supply chains and competitive positioning across industrial, technology, energy, health care and consumer markets. Its studies help clients evaluate strategic and investment decisions with documented assumptions and industry context.

Contact Us
Credence Research Inc. 
Tower C-1105, S 25, Akash Tower
Vishal Nagar, Pimple Nilakh, Haveli, Pune 411027, India 
USA: +1-888-600-6441 
sales@credenceresearch.com 
www.credenceresearch.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/dimethylaminopropylamine-market-to-reach-usd-731-9-million-by-2035-on-surfactant-and-epoxy-demand-credence-research-finds-302918151.html

Continue Reading

Technology

Misty Ventures and Aplicata Technologies Announce Strategic Partnership to Pursue Canadian Defence Opportunities

Published

47 minutes ago

on

October 23, 2026

By

Together, Aplicata and Misty Ventures will leverage their respective expertise, networks, and resources to support the commercialization of innovative technologies and help bring impactful solutions to government and public-sector markets.

SASKATOON, SK, Oct. 23, 2026 /PRNewswire-PRWeb/ — Misty Ventures, the economic development arm of Mistawasis Nêhiyawak, and Aplicata Technologies, a trusted leader in high-performance computing platforms for mission-critical defence applications, today announced they have signed a Memorandum of Understanding to explore a strategic partnership focused on pursuing and strengthening Canadian defence market opportunities.

“Partnering with Misty Ventures allows us to bring our capabilities to the Canadian defence market in a way that also creates lasting economic benefit for Mistawasis Nêhiyawak. We’re excited about the opportunity to build something meaningful together.” Mohammad Darwish, CEO of Aplicata.

Aplicata and Misty Ventures have agreed to form a Saskatchewan-based joint venture to develop and commercialize electronic warfare (EW), signals intelligence (SIGINT) and intelligence, surveillance and reconnaissance (ISR) technologies for Canadian defence.

The joint venture will deliver solutions across uncrewed aerial vehicles, aircraft, ground vehicles and naval vessels, providing the Canadian Armed Forces with a decisive operational advantage through advanced, mission-critical technology. It brings together Aplicata’s engineering, manufacturing and market expertise with Misty Ventures’ business development experience and its access to skilled talent and defence markets.

A guiding principle of the partnership is to build upon the strong business acumen, entrepreneurial capacity, and strategic vision of Mistawasis Nêhiyawak and its affiliated Indigenous communities. Through this partnership, Mistawasis Nêhiyawak seeks to leverage these strengths to contribute meaningfully to Canada’s defence priorities, supporting the development of sovereign capabilities, domestic innovation, and resilient Canadian supply chains. In addition to technology licensing, Aplicata intends to support the partnership through advanced knowledge and skills development, enabling Mistawasis Nêhiyawak to further expand its participation in Canada’s defence and security ecosystem and create lasting economic opportunity.

“This partnership reflects our commitment to building long-term, sustainable economic opportunities for Mistawasis Nêhiyawak and our broader community,” said Robert Daniels, Chief Executive Officer of Misty Ventures. “By combining our experience and market reach with Aplicata’s proven technology and market expertise, we believe we can create a defence sector business that delivers real value for Canada while creating meaningful opportunities for our people.”

“Aplicata brings a long history of innovation in advanced technologies for defence,” said Mohammad Darwish, Chief Executive Officer of Aplicata Technologies. “Partnering with Misty Ventures allows us to bring our capabilities to the Canadian defence market in a way that also creates lasting economic benefit for Mistawasis Nêhiyawak. We’re excited about the opportunity to build something meaningful together.”

About Misty Ventures

Since 2015, Misty Ventures has been the economic development entity of Mistawasis Nêhiyawak, growing through strategic partnerships across Saskatchewan’s construction, mining, oil and gas, and renewable energy sectors. Misty Ventures continues to pursue investments and collaborations aligned with its vision, mission, and values.

www.mistyventures.ca

About Aplicata Technologies

Aplicata is a trusted leader in high-performance computing platforms for mission-critical defence applications. We create innovative solutions engineered for performance and reliability, delivering results our customers can depend on. Rooted in a culture of collaboration and driven by a shared sense of purpose, we serve government and commercial organizations alike, pushing the boundaries of technology to enable new possibilities.

www.aplicata.com

Media Contact

Media Relations, Aplicata Technologies, 1 (844) 250-6300, media@aplicata.com, www.aplicata.com

View original content to download multimedia:https://www.prweb.com/releases/misty-ventures-and-aplicata-technologies-announce-strategic-partnership-to-pursue-canadian-defence-opportunities-302917752.html

SOURCE Aplicata Technologies

Continue Reading

Trending